Skip to content
★ Sign in to follow
Avalyn Pharma Inc. logo

Avalyn Pharma Inc. Stock: price and insider trades · United States

US·Mcap US$1.4BHealth Care

No insider purchase over the last 90 days. The latest, by Novo Holdings A/S, was filed 05 May 2026.

Insider Decl.
21
Thresholds
n/a
Buy Volume
€17M
3 ops. · all time
Sell Volume
€6M
4 ops. · all time

Avalyn Pharma Inc.: what insiders have been doing

Every trade that managers of Avalyn Pharma Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. From 14 November 2025 to 14 November 2026, the disclosure feed for Avalyn Pharma Inc. logged 20 filings by 5 insiders.

Purchases and sales both appear in the filings: 3 purchases (2 insiders, €17.1M) and 4 sales (1 insider, €6.0M). Netting one side against the other leaves €11.1M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Those buying include 2 major shareholders. At €8.5M, the purchase published on 5 May 2026 by Novo Holdings A/S is the largest of the period.

In the case of 3 purchases, another manager of the company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The most recent open-market purchase was published on 5 May 2026, 196 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify.

With 20 filings in twelve months, the company is quieter than the median of 24 filings across the 3,183 companies we follow on the same exchange. Since 2026, the database holds 3 purchases and 4 sales by insiders of the company.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and Drägerwerk AG & Co. KGaA. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.

Who traded when

BuySale
FMR LLC4 sales
SR One Capital Management, LLC2 buys
Novo Holdings A/S1 buy

Since the insiders bought

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

as of FY 2025

FY ended December 2025 · cache

US$30.59
Analyst consensus
5 analysts
1.40/5
US$52.00Target US$61.80(+102%)US$80.00
Income statement
EBITDA-US$91.3M
Net income-US$85.2M0.0% margin
Valuation
PER (forward)-11.9x
P/Book2.6x
Balance sheet & cash
Market capUS$1.4B
Total debtUS$1.7M
Free Cash Flow-US$81.8M
Debt / Equity4%
Profitability & ownership
ROE-68.3%
ROA-41.7%
% institutions105.3%
Last declaration on 12 November 2026

T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.

Declarations21 total
  • ▼
    Related company / holdingExecutives
    5M USD29SEC
    173,661 shares@ US$29.060.49% mcap75.4% of flowCommon StockSEC:0001193125-26-457571:0
  • ▼
    Related company / holdingExecutives
    39,835 USD11SEC
    1,339 shares@ US$29.750.0038% mcap0.6% of flowCommon StockSEC:0001193125-26-457571:1
  • ▼
    Related company / holdingExecutives
    164,501 USD13SEC
    5,565 shares@ US$29.560.016% mcap2.4% of flowCommon StockSEC:0001193125-26-457571:2
  • ▼
    Related company / holdingExecutives
    1M USD20SEC
    47,889 shares@ US$30.280.14% mcap21.5% of flowCommon StockSEC:0001193125-26-457571:3
  • ▲
    Related company / holdingExecutives
    10M USD28SEC
    555,555 shares@ US$18.00100.0% of flowVoting Common StockSEC:0001388325-26-000021:1
    Canonical exit: 30 Jul 2026 (T+90)
  • ●
    Related company / holdingExecutives
    0SEC
    727,585 sharesCommon StockSEC:0001193125-26-205201:0
  • ●
    Related company / holdingExecutives
    0SEC
    80,291 sharesCommon StockSEC:0001193125-26-205201:1
  • ●
    Related company / holdingExecutives
    0SEC
    872,868 sharesCommon StockSEC:0001193125-26-205201:2
  • ●
    Related company / holdingExecutives
    0SEC
    225,843 sharesCommon StockSEC:0001193125-26-205201:3
  • ●
    Related company / holdingExecutives
    0SEC
    377,948 sharesCommon StockSEC:0001193125-26-205201:4
  • ●
    Related company / holdingExecutives
    0SEC
    3,327,734 sharesVoting Common StockSEC:0001388325-26-000021:0
  • ▲
    DirectorExecutives

    Same trade as the filing by SR One Capital Management, LLC, counted once

    5M USD31SEC
    277,778 shares@ US$18.000.29% mcap100.0% of flowCommon StockSEC:0001193125-26-201894:2
    Canonical exit: 30 Jul 2026 (T+90)
  • ▲
    Related company / holdingExecutives
    5M USD22SEC
    277,777 shares@ US$18.000.29% mcap50.0% of flowCommon StockSEC:0001193125-26-201887:5
    Canonical exit: 30 Jul 2026 (T+90)
  • ▲
    Related company / holdingExecutives
    5M USD22SEC
    277,778 shares@ US$18.000.29% mcap50.0% of flowCommon StockSEC:0001193125-26-201887:2
    Canonical exit: 30 Jul 2026 (T+90)
  • ●
    Related company / holdingExecutives
    0SEC
    1,419,298 sharesCommon StockSEC:0001193125-26-201887:0
  • ●
    Related company / holdingExecutives
    0SEC
    489,486 sharesCommon StockSEC:0001193125-26-201887:1
  • ●
    Related company / holdingExecutives
    0SEC
    1,275,486 sharesCommon StockSEC:0001193125-26-201863:0
  • ●
    Related company / holdingExecutives
    0SEC
    354,824 sharesCommon StockSEC:0001193125-26-201887:3
  • ●
    Related company / holdingExecutives
    0SEC
    489,486 sharesCommon StockSEC:0001193125-26-201887:4
  • ●
    DirectorExecutives
    0SEC
    1,419,298 sharesCommon StockSEC:0001193125-26-201894:0
  • ●
    DirectorExecutives
    0SEC
    489,486 sharesCommon StockSEC:0001193125-26-201894:1

21 of 21 declarations

About Avalyn Pharma Inc.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations

The weekly insider digest, free

One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.